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Psoriasis is a cutaneous, chronic inflammatory
disorder that affects approximately 3.1% of US adults
younger than 60 years1 and up to 2.1% of children
worldwide.2,3 Chronic plaque psoriasis is generally
the most common type of childhood psoriasis
(accounting for 74% of cases in one study), followed
by guttate psoriasis (9.7%-28.9%), which is often
triggered by streptococcal infection.4 Standardized
guidelines for treating childhood psoriasis are lack-
ing, and there are only limited evidence-based data
and approved treatments. Case reports, therefore,
can be an important source of guidance for
clinicians.3 This case report discusses encouraging
outcomes obtained with apremilast in an adolescent
patient.
CASE REPORT
A 14-year-old boy with severe psoriasis affecting
the extremities, scalp, face, torso, and genitalia
returned to the clinic after a 5-year absence. The
patient had guttate psoriasis diagnosed originally at
age 8, which quickly progressed to plaque psoriasis
involving approximately 30% of the body surface
area (BSA). Despite treatment with topical therapies
and limited exposure to sunlight, he never obtained
a clinically meaningful response. His parents were
unwilling to have him undergo treatment with
narrowband ultraviolet B therapy because of the
inconvenience of the procedure, and they also
refused the use of systemic agents such as cyclo-
sporine and methotrexate because of their potential
side effects. The patient was unable to tolerate
etanercept injections. However, his psoriasis re-
mained in relative remission during his absence,
controlled only by sunlight.
At the time of his return to the clinic, the patient
was estimated to have 40% BSA involvement, char-
acterized by a widespread guttate pattern coalescingill Dermatology, LLC.
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rt Mill, SC 29708. E-mail: info@fortmillderm.com.into plaques in various places and severe pruritus.
His lesions were so pruritic that he often drew blood
when scratching his lower legs. His family had begun
homeschooling him several years earlier because he
had become withdrawn and less socially confident,
which they attributed to his skin disease. He was
prescribed an antibiotic to control the streptococcal
infection that presumably triggered the flare, along
with midpotency triamcinolone 0.1% cream to
minimize symptoms. One month later, his condition
had worsened (now 50% BSA), and he was
prescribed alternative topical corticosteroids at
higher potencies, depending on lesion location.
Systemic treatment options were again reviewed
with his family.
At his next visit 1.5 months later, his condition had
improved (approximately 25% BSA), aided by
greater sunlight exposure during the summer
months (Fig 1). His compliance with topical therapy
may have been suboptimal, as he generally resisted
applying any topical agents, including moisturizers.
Apremilast was selected as systemic therapy and was
prescribed at the adult dose of 30 mg twice daily,
based on the patient’s height and weight (182.9 cm
[72 inches] and 98.9 kg [218 pounds], respectively).
The recommended titration schedule for apremilast
was followed, and all other therapies were discon-
tinued by patient choice.
Clinically significant improvement was observed
after 1 month of apremilast therapy (Fig 2). During
the apremilast therapy, the patient was exposed only
to normal ambient sunlight and did not receive any
increased exposure. Although BSA was basically
unchanged, the plaques were thinner, less scaly,JAAD Case Reports 2016;2:89-91.
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Fig 1. Severely pruritic plaque psoriasis on lower extrem-
ities before apremilast treatment.
Fig 2. Significant clinical improvement after 1 month
of apremilast treatment. Plaques are thinner, less scaly,
lighter in color, and less pruritic.
Fig 3. Plaques on lower extremities are beginning to clear
after 2 months of apremilast treatment.
Fig 4. Hair regrowth and continued improvement after
6 months of apremilast treatment.
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As anticipated, the patient refused to apply
moisturizers. By the second month of therapy, the
plaques had further thinned (Fig 3), and the scalp
was beginning to clear. His demeanor was signifi-
cantly brighter than on previous visits.
During the third month of apremilast treatment,
the patient contracted a streptococcal infection,
which led to a temporary guttate flare. The infection
was managed with oral antibiotics, which quickly
resolved the flare while the patient maintained
treatment with apremilast. After 6 months of
apremilast therapy, the patient’s mother was tearfully
appreciative of the benefits her son had received
from the treatment, in terms of both his skin
condition and his psychological well-being. She
remarked that she no longer needed to change his
sheets every couple of days or vacuum the couch
after her son had been sitting on it. His scalp hair and
leg hair had resumed growing (Fig 4). The
patient reported no gastrointestinal upset as long as
he took apremilast with food. Since beginning
apremilast over 9 months ago, he has grown an
additional 5.1 cm (2 inches) and added 2.7 kg
(6 pounds).DISCUSSION
Apremilast is a small-molecule, oral phospho-
diesterase-4 inhibitor that works intracellularly to
regulate production of pro- and anti-inflammatory
mediators.5 It is approved for the treatment of adult
patients with active psoriatic arthritis and for mod-
erate to severe plaque psoriasis in patients who are
candidates for phototherapy or systemic therapy.
However, its safety and effectiveness have not been
established in pediatric patients. A search of the
published literature found no publications descri-
bing the use of apremilast in children or adolescents.
In the case described here, treatment with
apremilast led to noticeable improvements in the
patient’s psoriasis and his quality of life, in contrast to
topical therapies, which had been ineffective. The
observed benefits were most likely a direct result of
apremilast, as it was used in the absence of any
concomitant medications or moisturizers. This
young adolescent patient experienced no intolerable
gastrointestinal symptoms despite receiving the
adult dose of apremilast. He continues to be treated
with apremilast with no plans to discontinue
therapy. Although the family initially paid out of
pocket for his medical care, the patient subsequently
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appeals, coverage for his apremilast treatment.
In the management of psoriasis in children and
adolescents, the psychological aspects of the
condition should be considered. Psoriasis is a
chronic and potentially disfiguring disease that can
affect a patient’s self-image. A study examining
health-related quality of life in children with chronic
skin diseases found that the greatest impact on
health-related quality of life occurred with psoriasis
and atopic dermatitis, and this impact ranked only
slightly behind that of cerebral palsy, when
compared with other chronic diseases.6 An addi-
tional factor in the management of psoriasis is the
importance of educating patients and their families
on the need to adhere with treatment, toward the
goal of controlling the disease and prolonging the
period between flares.7 Children and adolescents
with moderate to severe psoriasis may be less
receptive than adults to treatment with biological
agents requiring injections. As illustrated by this case
report, oral apremilast may be an effective, well-
tolerated treatment option for adolescent patients
with psoriasis; however, clinical trial data arenecessary to fully understand the safety and efficacy
of apremilast in these patients.
Editorial support was provided by Gary Cooper, PhD,
of p-value communications, Cedar Knolls, NJ, and funded
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